Thu.Apr 11, 2024

article thumbnail

The Five Most Momentous Legal Tech Fails

Law Sites

While the last few years have brought an abundance of new and innovative legal tech products to market, the fact of the matter is that not every new product will succeed. Inevitably, for whatever reason, some products fail. But one thing for certain is that while some products shut down with a whimper, others go out with a bang. Let’s revisit five of the most momentous legal tech fails of the last 10 years. 1.

article thumbnail

Attorney Newsletters: Six Lawyers Tell How They Built the Best Newsletters in Their Niche

Attorney at Work

The Planetary Lawyer Project’s Matthew Karmel talks with Alex Su, Amee Vanderpool, Chris Harvey, Jonah Perlin and Albert Tawil about building a successful attorney newsletter in your niche. The business community knows the value and staying power of newsletters: Recent studies show the return on investment for email marketing is $36 for every $1 spent. […] The post Attorney Newsletters: Six Lawyers Tell How They Built the Best Newsletters in Their Niche appeared first on Articles, Tips and

213
213
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

April 2024 Feature Release

Lawmatics

April Fools’ Day may have been last week, but these new features are no joke. We’ve got a trio of updates for managing your matters, calendars, and finances. You’ll also find some quality-of-life tweaks that’ll simplify things for our intake coordinators and office managers out there. Filter and sort your table of matters We've revamped our classic matter table for a smoother user experience.

147
147
article thumbnail

Schiff Introduces Bill to Mandate Disclosure of Copyrighted Content Used to Train GAI Models

IP Watchdog

On April 9, Representative Adam Schiff (D-CA) introduced the Generative AI Copyright Disclosure Act of 2024 into the U.S. House of Representatives. The bill, which would require generative artificial intelligence (AI) platforms to disclose their use of copyrighted works in training AI models with retroactive effect, comes after months of growing concerns by the global creative community over the misappropriation of original works of authorship by companies collecting such content without prior a

article thumbnail

Trial Prep: What Attorneys Really Want (And How to Deliver It)

Speaker: Joe Stephens, J.D., Attorney and Law Professor

Get ready to uncover what attorneys really need from you when it comes to trial prep in this new webinar! Attorney and law professor, Joe Stephens, J.D., will share proven techniques for anticipating attorney needs, organizing critical documents, and transforming complex information into compelling case presentations. Key Learning Objectives: Organization That Makes Sense 🎯 Learn how to structure and organize case materials in ways that align with how attorneys actually work and think.

article thumbnail

Bayh-Dole Coalition: Activist Groups’ Bid for Medicare to Make Generic Xtandi is a ‘Desperate Ploy’

IP Watchdog

On April 9, Knowledge Ecology International (KEI), the Union for Affordable Cancer Treatment (UACT) and Universities Allied for Essential Medicines (UAEM) sent a letter to Chiquita Brooks-LaSure, Administrator for the Centers for Medicare and Medicaid Services, requesting that CMS use alleged statutory authority to allow companies to make and sell generic versions of the blockbuster prostate cancer drug, Xtandi®.

111
111
article thumbnail

CAFC Panel Splits on Reasonable Expectation of Success Analysis

IP Watchdog

In a precedential decision authored by Judge Lourie, the U.S. Court of Appeals for the Federal Circuit affirmed a district court’s final judgment that certain claims of several patents owned by Salix Pharmaceuticals for a drug used to treat irritable bowel syndrome (IBS) and other ailments were invalid as obvious. The CAFC also affirmed an order of the district court that instructed the Food and Drug Administration (FDA) that the effective approval date of generic company Norwich’s Abbreviated N